摘要
替米沙坦80mg/氢氯噻嗪12.5mg固定复方制剂是一种新型抗高血压药物。临床资料表明,替米沙坦80mg/氢氯噻嗪12.5mg固定复方制剂显著降低血压,安全性与安慰剂相似。本文主要从替米沙坦80mg/氢氯噻嗪12.5mg固定复方制剂药理学性质、临床疗效、安全性及耐受性几个方面进行综述。
Telmisartan 80mg/hydrochlorothiazide（HCTZ）12. 5mg fixed-dose combinations （FDC） of is a new antihypertensive drug. Clinical datas show that telmisartan 80mg/HCTZ 12. 5mg FDC can significantly reduct in blood pressure, the antihypertensive efficacy has been demonstrated in several large, randomized trials in hypertension patients, and safety is similar to placebo. This paper mainly summa- rized from telmisartan 80mg/HCTZ 12. 5mg FDC pharmacological properties, clinical efficacy, safety and tolerability aspects.
出处
《中国药物评价》
2013年第6期357-359,363,共4页
Chinese Journal of Drug Evaluation
关键词
高血压
替米沙坦
氢氯噻嗪
Hypertension
Telmisartan
Hydrochlorothiazide
